Adverse Events in Patients with Inflammatory Bowel Disease Treated with Advanced Therapies: A Nationwide, Population-Based, Propensity-Matched Cohort Study.

J Clin Med · 2026 · PMC13073948 · PMID 41976865

Europe PMC DOI

hedged sentence

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

borderline significantp = 0.052so close (0.05 < p ≤ 0.1)

Those treated with non–anti-TNF biologics had a lower IR of 1679.0 and a borderline significant reduction in risk (HR = 0.8, 95% CI = 0.7–1.0, p = 0.052).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.